Update: Takeda bets $400m in cash on colorectal cancer drug to boost China's Hutchmed - Endpoints News
  1. Update: Takeda bets $400m in cash on colorectal cancer drug to boost Hutchmed in China  Terminal news
  2. Why HUTCHMED (HCM) stocks are gaining today  Benzinga
  3. Takeda and Hutchmed team up on cancer drug for $1.13 billion  FiercePharma
  4. Takeda to Acquire Exclusive Worldwide License (Excluding China) of Fruquintinib from HUTCHMED, a Highly Selective Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor  business thread
  5. Takeda invests $1 billion more for colorectal cancer drug from Hutchmed  BioSpace
  6. See full coverage on Google News

Leave a Reply

Your email address will not be published.